[HTML][HTML] Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
Background Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization
or death in older patients and those with underlying conditions. Sotrovimab is a pan-…
or death in older patients and those with underlying conditions. Sotrovimab is a pan-…
Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial
…, E Alexander, WW Yeh, C Brinson, M Aldinger… - Jama, 2022 - jamanetwork.com
Importance Older patients and those with comorbidities who are infected with SARS-CoV-2
may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody …
may be at increased risk of hospitalization and death. Sotrovimab is a neutralizing antibody …
Effect of the neutralizing SARS-CoV-2 antibody sotrovimab in preventing progression of COVID-19: a randomized clinical trial
…, E Alexander, WW Yeh, C Brinson, M Aldinger… - medRxiv, 2021 - medrxiv.org
Importance Older patients and those with underlying comorbidities infected with SARS-CoV-2
may be at increased risk of hospitalization and death from COVID-19. Sotrovimab is a …
may be at increased risk of hospitalization and death from COVID-19. Sotrovimab is a …
Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study
…, EH Sarkis, A Lopuski, A Peppercorn, M Aldinger… - Future …, 2023 - Future Medicine
Aim: Sotrovimab is an engineered human monoclonal antibody that binds a conserved region
of the SARS-CoV-2 spike protein. The COMET-ICE phase III study evaluated sotrovimab …
of the SARS-CoV-2 spike protein. The COMET-ICE phase III study evaluated sotrovimab …
Safety, virology, pharmacokinetics, and clinical experience of high-dose intravenous sotrovimab for the treatment of mild to moderate COVID-19: an open-label clinical …
…, A El-Zailik, JE Sager, M Aldinger… - Open Forum …, 2023 - academic.oup.com
Background Five hundred milligrams of intravenous (IV) sotrovimab has been shown to be
well tolerated and efficacious against pre-Omicron strains in treating patients with mild to …
well tolerated and efficacious against pre-Omicron strains in treating patients with mild to …
Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab (preprint)
Background: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization
and death in older patients and those with underlying comorbidities. Sotrovimab is a pan-…
and death in older patients and those with underlying comorbidities. Sotrovimab is a pan-…
1150. Resistance analysis in the COMET-TAIL study: participants with mild-to-moderate COVID-19 treated with intramuscular or intravenous sotrovimab
…, A Skingsley, LA Gaffney, M Aldinger… - Open Forum …, 2022 - academic.oup.com
Background Sotrovimab (VIR-7831) is an engineered human monoclonal antibody
targeting a conserved region of the SARS-CoV-2 spike protein; it has been shown to have a …
targeting a conserved region of the SARS-CoV-2 spike protein; it has been shown to have a …
Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19
…, S Roepcke, X Li, M Aldinger… - CPT …, 2023 - Wiley Online Library
Sotrovimab is a recombinant human monoclonal antibody that has been shown to prevent
progression to hospitalization or death in non‐hospitalized high‐risk patients with mild to …
progression to hospitalization or death in non‐hospitalized high‐risk patients with mild to …
[HTML][HTML] Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19
…, TJH Keeley, HJ Birch, D Brintziki, M Aldinger… - Journal of Patient …, 2023 - Springer
Background The COMET-ICE trial demonstrated that sotrovimab clinically and statistically
significantly reduces the risk of all-cause > 24-h hospitalization or death due to any cause …
significantly reduces the risk of all-cause > 24-h hospitalization or death due to any cause …
[HTML][HTML] 1154. Safety, Tolerability, and Viral Pharmacodynamics of the IgG Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection for the Treatment …
…, S Segal, A Skingsley, M Aldinger… - Open Forum …, 2022 - ncbi.nlm.nih.gov
… Anil K Gupta, MD, Maria Teresa Perez-Rodríguez, MD, Yaneicy Gonzalez-Rojas, MD, Moti
Ramgopal, MD, FACP, FIDSA, Almena Free, MD, Jennifer Han, MD, Jennifer Moore, MD, Rudrani …
Ramgopal, MD, FACP, FIDSA, Almena Free, MD, Jennifer Han, MD, Jennifer Moore, MD, Rudrani …